Can You Take Wegovy Fortnightly? The Dosing Schedule Explained

Wegovy (semaglutide) is injected once every seven days — not fortnightly, not twice weekly.
The titration schedule increases the dose roughly every four weeks: 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg (or up to 7.2 mg via the newer dosing pathway).
Missing or extending doses disrupts the steady blood level that underpins the medicine's appetite-regulating effect.
If a dose is missed, the guidance is to check the Patient Information Leaflet and speak to your prescriber, the right action depends on timing, not a general rule.

No — Wegovy is not designed to be taken fortnightly. It is a once-weekly injection, and that weekly frequency is a core part of how the medicine maintains steady semaglutide levels in your body. Stretching doses to every two weeks is not supported by the licensed dosing schedule and could affect how well it works. That said, the question makes sense: the titration ladder means you spend several weeks on each dose before moving up, and people sometimes confuse the monthly prescription cycle with the actual injection frequency. How Wegovy is taken is worth understanding clearly before you start, so this page sets out what the schedule genuinely looks like and why it is structured the way it is. Wegovy is a prescription-only medicine; a GPhC-registered prescriber assesses whether it is suitable for you before anything is dispensed.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

Why weekly matters, and what happens when the schedule shifts

The myth: Wegovy can be spread out to save pens or reduce side effects

This is the misconception that brings most people to this question. Semaglutide has a long half-life (around a week) which is precisely why it is formulated as a once-weekly injection rather than a daily one. That pharmacokinetic profile means weekly dosing keeps levels broadly stable. Stretching to fortnightly doses does not simply halve the effect; it allows levels to drop lower between injections, potentially reducing appetite suppression and disrupting the steady state the medicine depends on.

Some people consider a fortnightly approach hoping it will ease nausea. That instinct is understandable, semaglutide's most common side effects are gastrointestinal, and they tend to surface after a dose. But the licensed titration schedule already addresses this: the 0.25 mg starting dose exists precisely to give your body time to adjust, not to produce significant weight loss. Slowing further by injecting fortnightly is not recommended and is not covered by the medicine's approval. The NHS semaglutide guidance is clear that the injection is taken once a week, on the same day each week.

The other version of this myth is cost-driven: a single pen lasts four weeks at weekly dosing, so a fortnightly plan might seem to stretch supply. That reasoning inverts the logic. The pen's dose per injection is calibrated to the weekly interval. Taking it less often is not a way to make treatment last longer, it is a departure from the licensed schedule that a prescriber cannot recommend.

What the actual Wegovy schedule looks like week by week

The standard titration pathway for Wegovy injection runs in roughly four-week steps: 0.25 mg for the first four weeks, then 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg as the maintenance dose. For some patients, a 7.2 mg maintenance dose is now an option following MHRA approval in January 2026, reached via the same gradual titration. Your prescriber decides the pace based on how your body responds, not a fixed calendar.

Each step takes four weeks partly because that is long enough to reach a new steady state and assess tolerability. It is not four separate fortnightly injections, it is four weekly injections at the same strength. That distinction matters. If you are collecting a monthly supply, what arrives is four pens' worth of the current dose, one per week.

Injection day is your choice, and keeping it consistent is what matters. Some people find a specific time of day or evening works better for managing any side effects around the injection window. The day can shift by a day or two in a given week if needed, but a reliable seven-day rhythm keeps levels stable. For a detailed look at technique and practicalities, the full Wegovy administration guide covers what to expect when you open the box.

Missed doses and what to do instead of extending the interval deliberately

Life happens, and occasionally a weekly dose is late or missed. The Patient Information Leaflet sets out the specific guidance for this situation, the right action depends on how many days have passed since the missed dose was due, and that detail changes what you should do. A prescriber or pharmacist is the right person to ask if you are unsure. What is clear is that a missed dose is different from a deliberate policy of fortnightly injections: one is an occasional disruption, the other is a sustained change to the dosing schedule that has no clinical support.

If the side-effect burden is the real concern, there are evidence-based ways to manage it alongside the licensed schedule: smaller, lower-fat meals, staying well hydrated, and timing the injection to fit around your week. For people genuinely struggling to tolerate dose increases, the right conversation is with a prescriber about whether to stay at the current dose for longer, not about stretching the interval independently. If you are also wondering about long-term planning (how long Wegovy treatment typically runs and what happens if you stop) those are separate, important questions worth reading about.

At nume, every repeat order is reviewed by a real prescriber before it is dispensed. When your pen arrives (tracked by DPD, in plain packaging) the clinical check behind it has already confirmed that the current dose and schedule are still appropriate for you. That review is not a formality. It is the point at which any concerns about tolerability, timing or the schedule itself can actually be addressed.

Wegovy is a prescription-only medicine. Questions about your specific dosing should go to your prescriber or the NHS semaglutide patient information, never a general guide. If you have not yet started treatment and want to understand whether semaglutide is clinically suitable for you, you can begin a free consultation with our prescribers.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions